Panbela Therapeutics (NASDAQ:PBLA) Stock Price Up 1.6%

Shares of Panbela Therapeutics, Inc. (NASDAQ:PBLA) traded up 1.6% on Monday . The stock traded as high as $0.38 and last traded at $0.36. 2,431 shares changed hands during trading, a decline of 99% from the average session volume of 258,061 shares. The stock had previously closed at $0.35.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Panbela Therapeutics in a research report on Thursday, August 15th.

Panbela Therapeutics Price Performance

The business has a 50 day simple moving average of $0.36 and a 200 day simple moving average of $0.42. The company has a market capitalization of $1.24 million, a price-to-earnings ratio of 0.00 and a beta of 1.62.

Panbela Therapeutics (NASDAQ:PBLA) last announced its earnings results on Tuesday, August 13th. The company reported ($1.47) EPS for the quarter, beating analysts’ consensus estimates of ($2.07) by $0.60. On average, equities research analysts predict that Panbela Therapeutics, Inc. will post -6.76 EPS for the current year.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.